Jessica Nagel

Jessica Nagel

Auto-generated profile, based on publicly available information

Jessica Nagel

Pharmaceutical & Medicinal Chemistry, PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AOAdam C. Oken
Adam C. Oken
ATANDREEA LARISA TURCU
ANDREEA LARISA TURCU
ETEva Tzortzini
Eva Tzortzini
KGKyriakos Georgiou
Kyriakos Georgiou
JNJessica Nagel
Jessica Nagel
SMSteven E. Mansoor
Steven E. Mansoor
The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential.

30 January 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
JNJessica Nagel
Jessica Nagel
CBChristiane Bous
Christiane Bous
AAAliaa Abdelrahman
Aliaa Abdelrahman
ASAnke C. Schiedel
Anke C. Schiedel
CMChrista Müller
Christa Müller

4 December 2025 in Nature Communications
Verified
Journal Article
Open access
JNJessica Nagel
Jessica Nagel
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
SWStephanie Weinhausen
Stephanie Weinhausen
JSJuan Sierra-Marquez
Juan Sierra-Marquez
Younis BaqiYounis Baqi
Younis Baqi
CMChrista Müller
Christa Müller
P2X receptors are trimeric ATP-gated ion channels. The P2X4 receptor subtype is a promising drug target for the treatment of inflammatory diseases, neuropathic pain, and cancer. Here, the water-soluble anthraquinone derivative Cibacron Blue, previously described as a P2X4 receptor modulator, is selected as a lead structure, and structure-activity relationships are investigated. A chimeric receptor approach, combined with mutagenesis and docking studies, is applied to identify the allosteric binding site and the interacting amino acid residues. We discover that Glu307, located in the upper body of the receptor, is prone to form an intermolecular “ionic lock” with basic amino acid residues, thereby preventing high-affinity binding of anthraquinone derivatives. Exchange of Glu307 for threonine leads to a dramatic potency increase for anthraquinones in blocking P2X4 receptor function. The structure of the human P2X4-E307T receptor in complex with the anthraquinone derivative PSB-0704 is determined by cryo-electron microscopy at a resolution of 3.35 Å. This reveals an allosteric binding site in the upper body at the interface of the receptor trimer subunits, which differs from previously described allosteric sites on P2X receptors. Our results provide a rational basis for structure-based drug design towards potent and selective P2X4 receptor antagonists.

16 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AOAdam C. Oken
Adam C. Oken
ATANDREEA LARISA TURCU
ANDREEA LARISA TURCU
ETEva Tzortzini
Eva Tzortzini
KGKyriakos Georgiou
Kyriakos Georgiou
JNJessica Nagel
Jessica Nagel
SMSteven E. Mansoor
Steven E. Mansoor
The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Interspecies variation among existing antagonists has proven challenging, in part due to the dearth of molecular information on different receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with new and existing structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with picomolar potency and high selectivity, revealing its significant therapeutic potential.